Literature DB >> 33725240

Circ_0023984 Facilitates Esophageal Squamous Cell Carcinoma Progression by Regulating miR-433-3p/REV3L Axis.

Ting Li1, Suping Li2.   

Abstract

BACKGROUND: It has been revealed that circular RNAs (circRNAs) play an important role in regulating the malignant phenotype of tumor cells, thus involving in the progression of malignancies. However, the role of circ_0023984 in esophageal squamous cell carcinoma (ESCC) remains largely unclear.
METHODS: The quantitative real-time polymerase chain reaction and Western blot assays were used to detect the expression of circ_0023984, microRNA (miR)-443-3p, and protein reversionless 3-like (REV3L). In vitro and in vivo assays were performed using cell counting kit-8, colony formation, transwell, wound healing, flow cytometry, and xenograft assays. The interaction miR-433-3p and circ_0023984 or REV3L was confirmed by dual-luciferase reporter, pull-down or RIP assays.
RESULTS: Circ_0023984 was highly expressed in ESCC tissues and cells, knockdown of circ_0023984 suppressed cancer cell proliferation, migration, invasion, and promoted cell apoptosis in vitro. Mechanistic analysis confirmed that circ_0023984 functioned as a sponge for miR-433-3p to positively regulate the expression of REV3L that was verified to be a target of miR-433-3p. Circ_0023984 knockdown repressed the tumorigenesis of ESCC cells via targeting miR-433-3p. Additionally, miR-433-3p performed anti-proliferative, anti-migratory, and anti-invasive abilities in ESCC cells, which were reversed by REV3L overexpression. Pre-clinically, silencing of circ_0023984 suppresses the tumorigenesis and growth of xenografts in nude mice.
CONCLUSION: Circ_0023984 exerted an oncogenic role in ESCC tumorigenesis and aggressiveness through promoting cell growth, migration, and invasion via miR-433-3p/REV3L axis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer progression; Circ_0023984; Esophageal squamous cell carcinoma; MiR-433-3p; REV3L

Mesh:

Substances:

Year:  2021        PMID: 33725240     DOI: 10.1007/s10620-021-06916-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Esophageal carcinoma.

Authors:  Anil K Rustgi; Hashem B El-Serag
Journal:  N Engl J Med       Date:  2014-12-25       Impact factor: 91.245

2.  Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer.

Authors:  Jie Chen; Yan Li; Qiupeng Zheng; Chunyang Bao; Jian He; Bin Chen; Dongbin Lyu; Biqiang Zheng; Yu Xu; Ziwen Long; Ye Zhou; Huiyan Zhu; Yanong Wang; Xianghuo He; Yingqiang Shi; Shenglin Huang
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

3.  Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis.

Authors:  Kuei-Yang Hsiao; Ya-Chi Lin; Sachin Kumar Gupta; Ning Chang; Laising Yen; H Sunny Sun; Shaw-Jenq Tsai
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

4.  Molecular biology. A circuitous route to noncoding RNA.

Authors:  Jeremy E Wilusz; Phillip A Sharp
Journal:  Science       Date:  2013-04-26       Impact factor: 47.728

Review 5.  Screening for esophageal squamous cell carcinoma: recent advances.

Authors:  Don C Codipilly; Yi Qin; Sanford M Dawsey; John Kisiel; Mark Topazian; David Ahlquist; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2018-04-27       Impact factor: 9.427

6.  Detecting and characterizing circular RNAs.

Authors:  William R Jeck; Norman E Sharpless
Journal:  Nat Biotechnol       Date:  2014-05       Impact factor: 54.908

7.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 8.  Global Cancer Incidence and Mortality Rates and Trends--An Update.

Authors:  Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-14       Impact factor: 4.254

9.  Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma.

Authors:  Xiu-Yan Huang; Zi-Li Huang; Yong-Hua Xu; Qi Zheng; Zi Chen; Wei Song; Jian Zhou; Zhao-You Tang; Xin-Yu Huang
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

10.  CiRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/HOXB13.

Authors:  Rui-Chao Li; Shun Ke; Fan-Kai Meng; Jun Lu; Xiao-Jing Zou; Zhi-Gang He; Weng-Feng Wang; Ming-Hao Fang
Journal:  Cell Death Dis       Date:  2018-08-06       Impact factor: 8.469

View more
  5 in total

Review 1.  Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected.

Authors:  Chenxi Ju; Jing He; Chang Wang; Jinxiu Sheng; Jinlin Jia; Dan Du; Hongle Li; Mingxia Zhou; Fucheng He
Journal:  Biomark Res       Date:  2022-06-07

2.  CircRNA circ_0023984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis.

Authors:  Ge Yang; Yu Zhang; Hongni Lin; Jinnbo Liu; Shengjie Huang; Wei Zhong; Chao Peng; Lin Du
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Circular RNA CircPVT1 Inhibits 5-Fluorouracil Chemosensitivity by Regulating Ferroptosis Through MiR-30a-5p/FZD3 Axis in Esophageal Cancer Cells.

Authors:  Wenjian Yao; Jianjun Wang; Fanruo Meng; Zibo Zhu; Xiangbo Jia; Lei Xu; Quan Zhang; Li Wei
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 4.  MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.

Authors:  Janusz Matuszyk
Journal:  Mol Med       Date:  2022-08-03       Impact factor: 6.376

Review 5.  The role of MiRNA-433 in malignant tumors of digestive tract as tumor suppressor.

Authors:  Jie Tang; Jiawei Chen; Yongqiang Wang; Shaobo Zhou
Journal:  Cancer Rep (Hoboken)       Date:  2022-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.